New Two-Pronged cell therapy tested in Tough-to-Treat lymphoma
NCT ID NCT05149391
Summary
This early-stage study tested the safety of a new type of CAR-T cell therapy called C-CAR039 in three patients with B-cell lymphoma that had returned or not responded to other treatments. The therapy uses the patient's own modified immune cells to target two proteins (CD19 and CD20) on the cancer cells. The main goal was to check for side effects and see how the body handled the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.